
NHS weight loss jabs might 'not be suitable' for these 5 groups
GPs will be prescribing Mounjaro to a select few people as the rollout begins, but others may need to avoid the jabs completely
GPs can now prescribe Mounjaro, but only to a select group of patients who meet stringent criteria, such as having a BMI over 40 and being diagnosed with four out of five qualifying conditions. But people with other pre-existing conditions may not be able to access this weight loss drug at all.
Dr Crystal Willie from ZAVA clarified that weight loss drugs "may be unsafe depending on medications you are taking or pre-existing medical conditions". This includes three specific conditions:
Pancreatic disorders like pancreatitis
History of thyroid cancer
History of gallbladder disease
Women who are pregnant, breastfeeding or planning to do either might also be advised to avoid the medication. The same goes for people on certain medications like insulin or immunosuppressants.
Dr Willie told the Mirror: "You should speak to your doctor about any conditions or medications before taking any weight loss injection. Mounjaro weight loss injections can lower your blood sugar levels too much if taken in combination with sulfonylurea or insulin (other diabetes treatments).
"You shouldn't take Mounjaro alongside other weight loss injections, such as Saxenda or Wegovy. This could increase the risk of serious health risks and side effects."
The doctor also revealed that weight loss medication might actually not do what people think, as research from ZAVA found up to 20% of people using the GLP-1 drugs don't see the expected results or hit a weight loss plateau.
There are a variety of reasons for this, including:
Incorrect dosage
Missing doses
Not improving your diet and an inactive lifestyle
Not keeping hydrated
Excessive alcohol consumption
Persistent stress
Having a poor sleep routine
Other health conditions may interfere with the effectiveness of weight loss drugs, like diabetes, hypothyroidism, insulin resistance and PCOS. Medications like antidepressants or steroids may also cause weight gain or hinder fat loss.
Dr Wyllie added: "While Mounjaro is an effective medication for weight loss, it's normal to encounter a plateau at some point. To enhance your results, it's important to follow the prescribed dosing schedule and aim to reach the appropriate maintenance dose, as higher doses are generally associated with greater benefits.
"Beyond medication, factors like maintaining a balanced diet, regular physical activity, managing stress, and getting enough sleep play a crucial role in supporting your weight loss journey. If progress stalls despite these efforts, consulting your healthcare provider is essential to evaluate your plan and make necessary adjustments."

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Daily Mirror
5 hours ago
- Daily Mirror
NHS weight loss jabs might 'not be suitable' for these 5 groups
GPs will be prescribing Mounjaro to a select few people as the rollout begins, but others may need to avoid the jabs completely GPs can now prescribe Mounjaro, but only to a select group of patients who meet stringent criteria, such as having a BMI over 40 and being diagnosed with four out of five qualifying conditions. But people with other pre-existing conditions may not be able to access this weight loss drug at all. Dr Crystal Willie from ZAVA clarified that weight loss drugs "may be unsafe depending on medications you are taking or pre-existing medical conditions". This includes three specific conditions: Pancreatic disorders like pancreatitis History of thyroid cancer History of gallbladder disease Women who are pregnant, breastfeeding or planning to do either might also be advised to avoid the medication. The same goes for people on certain medications like insulin or immunosuppressants. Dr Willie told the Mirror: "You should speak to your doctor about any conditions or medications before taking any weight loss injection. Mounjaro weight loss injections can lower your blood sugar levels too much if taken in combination with sulfonylurea or insulin (other diabetes treatments). "You shouldn't take Mounjaro alongside other weight loss injections, such as Saxenda or Wegovy. This could increase the risk of serious health risks and side effects." The doctor also revealed that weight loss medication might actually not do what people think, as research from ZAVA found up to 20% of people using the GLP-1 drugs don't see the expected results or hit a weight loss plateau. There are a variety of reasons for this, including: Incorrect dosage Missing doses Not improving your diet and an inactive lifestyle Not keeping hydrated Excessive alcohol consumption Persistent stress Having a poor sleep routine Other health conditions may interfere with the effectiveness of weight loss drugs, like diabetes, hypothyroidism, insulin resistance and PCOS. Medications like antidepressants or steroids may also cause weight gain or hinder fat loss. Dr Wyllie added: "While Mounjaro is an effective medication for weight loss, it's normal to encounter a plateau at some point. To enhance your results, it's important to follow the prescribed dosing schedule and aim to reach the appropriate maintenance dose, as higher doses are generally associated with greater benefits. "Beyond medication, factors like maintaining a balanced diet, regular physical activity, managing stress, and getting enough sleep play a crucial role in supporting your weight loss journey. If progress stalls despite these efforts, consulting your healthcare provider is essential to evaluate your plan and make necessary adjustments."


BreakingNews.ie
6 hours ago
- BreakingNews.ie
Pancreatitis cases linked to weight loss jabs
Ireland's medicines watchdog has confirmed a number of reports of pancreatitis linked to weight loss jabs. GLP-1 drugs like Ozempic and Mounjaro are under review in the UK after a spike in adverse reactions. Advertisement The Health Products Regulatory Authority (HPRA) said the number of Irish cases is very low, but people should consult their doctor if they are concerned. HSE national clinical lead for obesity, Professor Donal O'Shea, said it is important people use these drugs under medical supervision. Prof O'Shea said: "The main side effects are gastrointestinal and that's around nausea, vomiting, constipation, but they can cause unsteadiness and dizziness. "And I've certainly seen people coming into hospital having had falls on these treatements, and again the advice is not to take these unless they are prescribed by a healthcare professional."

Leader Live
9 hours ago
- Leader Live
Weight loss jabs linked to potentially fatal side effects
Some cases of pancreatitis reported to be linked to GLP-1 medicines (glucagon-like peptide-1 receptor agonists) have been fatal. Data from the medicines regulator, the Medicines and Healthcare products Regulatory Agency (MHRA), shows that since the drugs were licensed there have been hundreds of cases of acute and chronic pancreatitis among people taking GLP-1 medicines. The new weight management medication 'Tirzepatide' (brand name Mounjaro®) is shortly being made available to NHS patients to support weight loss. Access is prioritised for those with the greatest clinical need. You can find out more at: This includes: These cases are not confirmed as being caused by the medicines, but the person who reported them suspected they may be. Review your ICB's local policy about treating patients with tirzepatide (Mounjaro) for weight management in a primary care setting and visit: Nonetheless, Yellow Card Biobank project, launched by the MHRA and Genomics England, will see researchers examine whether cases of pancreatitis linked to GLP-1 drugs may be influenced by peoples genetic makeup. The MHRA is calling for people who are taking GLP-1 medicine who have been admitted to hospital due to acute pancreatitis to submit a report to its Yellow Card scheme. When a Yellow Card report is received, the MHRA will contact patients to ask if they would be willing to take part in the study. Patients will be asked to submit more information and a saliva sample which will be assessed to explore whether some people are at a higher risk of acute pancreatitis when taking these medicines due to their genes. GLP-1 agonists can lower blood sugar levels in people living with type 2 diabetes and can also be prescribed to support some people with weight loss. 🧵Weight loss jab roll out 'positive for patients' but with implications for general practice that must be considered. Our Chair Kamila Hawthorne has featured widely in the national press and broadcast media responding to the phased roll-out of Mounjaro prescriptions by NHS… Chronic stress and poor sleep are major weight loss blockers. Stress increases cortisol, a hormone linked to fat retention, especially around the abdomen. Sleep deprivation increases ghrelin (hunger hormone) and decreases leptin (fullness hormone), making you more likely to overeat and less likely to move. You're also more impulsive and less motivated when sleep-deprived, making it harder to stick to your diet and exercise routine. As a solution, prioritise stress management techniques (like mindfulness or journaling), and aim for 7-9 hours of sleep per night. Medical issues such as PCOS, diabetes, hypothyroidism, or insulin resistance can all interfere with weight loss. Similarly, certain medications (like antidepressants or steroids) may cause weight gain or inhibit fat loss. If weight loss stalls despite doing everything right, consult your GP to rule out or address any underlying conditions. If you have a known medical condition, it's important to stay up to date with your routine reviews and inform your GP or specialist about any weight loss treatments you're using. Regular follow-up helps ensure your treatment plan remains safe and effective. More Mounjaro news... Recent estimates suggest that about 1.5 million people in the UK are taking weight loss jabs. Health officials have suggested that they can help to turn the tide on obesity, but have stressed they are not a silver bullet and do come with side effects. Most side effects linked to the jabs are gastrointestinal including nausea, constipation and diarrhoea. And the medical regulator recently warned that Mounjaro may make the oral contraceptive pill less effective in some patients. Dr Alison Cave, MHRA's chief safety officer, said: 'Evidence shows that almost a third of side effects to medicines could be prevented with the introduction of genetic testing, it is predicted that adverse drug reactions could cost the NHS more than £2.2 billion a year in hospital stays alone. 'Information from the Yellow Card Biobank will help us to better predict those most at risk of adverse reactions – enabling patients across the UK to receive the safest medicine for them, based on their genetic makeup. 'To help us help you, we're asking anyone who has been hospitalised with acute pancreatitis while taking a GLP-1 medicine to report this to us via our Yellow Card scheme. 'Even if you don't meet the criteria for this phase of the Biobank study, information about your reaction to a medication is always extremely valuable in helping to improve patient safety.' Professor Matt Brown, chief scientific officer of Genomics England, said: 'GLP-1 medicines like Ozempic and Wegovy have been making headlines, but like all medicines there can be a risk of serious side effects. 'We believe there is real potential to minimise these with many adverse reactions having a genetic cause. 'This next step in our partnership with the MHRA will generate data and evidence for safer and more effective treatment through more personalised approaches to prescription, supporting a shift towards an increasingly prevention-focused healthcare system.'